{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:28Z","timestamp":1789726228656,"version":"4.0.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T00:00:00Z","timestamp":1673740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.phrs.2023.106667","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T11:46:10Z","timestamp":1673869570000},"page":"106667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms"],"prefix":"10.1016","volume":"188","author":[{"given":"Elena","family":"Osto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Bonacina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Pirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Danilo","family":"Norata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2\u20133","key":"10.1016\/j.phrs.2023.106667_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mam.2012.11.002","article-title":"Glucose transport families SLC5 and SLC50","volume":"34","author":"Wright","year":"2013","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.phrs.2023.106667_bib2","first-page":"370","article-title":"Surprising versatility of Na+-glucose cotransporters: SLC5","volume":"19","author":"Wright","year":"2004","journal-title":"Physiol. (Bethesda)"},{"issue":"9","key":"10.1016\/j.phrs.2023.106667_bib3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/dom.12970","article-title":"Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes","volume":"19","author":"Solini","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2023.106667_bib4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2023.106667_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0006-2952(87)90389-3","article-title":"On the mode of action of phlorizin as an antimalarial agent in in vitro cultures of Plasmodium falciparum","volume":"36","author":"Kutner","year":"1987","journal-title":"Biochem Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2023.106667_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose Co-transporters and their inhibition: clinical physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.phrs.2023.106667_bib7","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1248\/cpb.44.1174","article-title":"Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4\u2032-dehydroxyphlorizin derivatives based on a new concept","volume":"44","author":"Tsujihara","year":"1996","journal-title":"Chem. Pharm. Bull."},{"issue":"3","key":"10.1016\/j.phrs.2023.106667_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"issue":"22","key":"10.1016\/j.phrs.2023.106667_bib9","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"E.-R.O. investigators, empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2023.106667_bib10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.phrs.2023.106667_bib11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"D.-T. Investigators, dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2023.106667_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/eurheartj\/ehx511","article-title":"E.-R.O.t. investigators, Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial","volume":"39","author":"Fitchett","year":"2018","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.phrs.2023.106667_bib13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.phrs.2023.106667_bib14","doi-asserted-by":"crossref","unstructured":"G. Savarese, B. Schrage, F. Cosentino, L.H. Lund, G.M.C. Rosano, P. Seferovic, J. Butler, Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials, ESC Heart Fail (2020).","DOI":"10.1002\/ehf2.12937"},{"issue":"10","key":"10.1016\/j.phrs.2023.106667_bib15","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/cvr\/cvab271","article-title":"Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms","volume":"118","author":"Savarese","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"22","key":"10.1016\/j.phrs.2023.106667_bib16","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.phrs.2023.106667_bib17","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"V.C. investigators, cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"23","key":"10.1016\/j.phrs.2023.106667_bib18","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"V.C. Investigators, efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.phrs.2023.106667_bib19","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"D.-H.T. Committees, investigators, dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.phrs.2023.106667_bib20","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"E.M.-R.T. Investigators, cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.phrs.2023.106667_bib21","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"E.M.-P.T. investigators, empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.phrs.2023.106667_bib22","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"D.T. Committees, investigators, dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2023.106667_bib23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.120.051675","article-title":"D.-C.T. Committees, investigators, effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.phrs.2023.106667_bib24","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1056\/NEJMc2112411","article-title":"Empagliflozin and major renal outcomes in heart failure","volume":"385","author":"Packer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2023.106667_bib25","unstructured":"E.-K.C. Group, W.G. Herrington, N. Staplin, C. Wanner, J.B. Green, S.J. Hauske, J.R. Emberson, D. Preiss, P. Judge, K.J. Mayne, S.Y.A. Ng, E. Sammons, D. Zhu, M. Hill, W. Stevens, K. Wallendszus, S. Brenner, A.K. Cheung, Z.H. Liu, J. Li, L.S. Hooi, W. Liu, T. Kadowaki, M. Nangaku, A. Levin, D. Cherney, A.P. Maggioni, R. Pontremoli, R. Deo, S. Goto, X. Rossello, K.R. Tuttle, D. Steubl, M. Petrini, D. Massey, J. Eilbracht, M. Brueckmann, M.J. Landray, C. Baigent, R. Haynes, Empagliflozin in Patients with Chronic Kidney Disease, N Engl J Med (2022)."},{"issue":"7","key":"10.1016\/j.phrs.2023.106667_bib26","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2337\/db16-0049","article-title":"Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism","volume":"65","author":"Briand","year":"2016","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.phrs.2023.106667_bib27","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"E.-R.M.T. Investigators, Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"Haring","year":"2014","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.phrs.2023.106667_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1479164120975256","article-title":"Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME((R)","volume":"17","author":"Langslet","year":"2020","journal-title":"Diab Vasc. Dis. Res"},{"issue":"6","key":"10.1016\/j.phrs.2023.106667_bib29","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/dom.13990","article-title":"The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well-controlled plasma LDL cholesterol","volume":"22","author":"Bouter","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"11","key":"10.1016\/j.phrs.2023.106667_bib30","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s12325-015-0255-8","article-title":"Effects of baseline blood pressure and low-density lipoprotein cholesterol on safety and efficacy of canagliflozin in japanese patients with type 2 diabetes mellitus","volume":"32","author":"Inagaki","year":"2015","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2023.106667_bib31","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/HJH.0000000000003106","article-title":"Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: a meta-analysis","volume":"40","author":"Geng","year":"2022","journal-title":"J. Hypertens."},{"issue":"2","key":"10.1016\/j.phrs.2023.106667_bib32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacl.2017.01.018","article-title":"Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels","volume":"11","author":"Bays","year":"2017","journal-title":"J. Clin. Lipido"},{"issue":"4","key":"10.1016\/j.phrs.2023.106667_bib33","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/oby.22748","article-title":"Efficacy and safety of ertugliflozin in patients with overweight and obesity with type 2 diabetes mellitus","volume":"28","author":"Heymsfield","year":"2020","journal-title":"Obes. (Silver Spring)"},{"issue":"11","key":"10.1016\/j.phrs.2023.106667_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166125","article-title":"Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Storgaard","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2023.106667_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105068","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials","volume":"160","author":"Sanchez-Garcia","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.106667_bib36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40780-020-00160-0","article-title":"Clinical relevance between sodium-glucose co-transporter 2 inhibitors and lipid profiles in Asian patients with type 2 diabetes mellitus: a systematic review with a meta-analysis of randomized controlled trials","volume":"6","author":"Mukai","year":"2020","journal-title":"J. Pharm. Health Care Sci."},{"issue":"1","key":"10.1016\/j.phrs.2023.106667_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-016-0491-5","article-title":"Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin","volume":"16","author":"Hayashi","year":"2017","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"10.1016\/j.phrs.2023.106667_bib38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-017-0529-3","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial","volume":"16","author":"Fadini","year":"2017","journal-title":"Cardiovasc Diabetol."},{"issue":"9","key":"10.1016\/j.phrs.2023.106667_bib39","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition","volume":"38","author":"Basu","year":"2018","journal-title":"Arterioscler., Thromb., Vasc. Biol."},{"key":"10.1016\/j.phrs.2023.106667_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109983","article-title":"Effect of empagliflozin on plasma proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with type 2 diabetes","volume":"190","author":"Trico","year":"2022","journal-title":"Diabetes Res Clin. Pr."},{"key":"10.1016\/j.phrs.2023.106667_bib41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2021.06.915","article-title":"Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study","volume":"330","author":"Rau","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106667_bib42","first-page":"1","article-title":"Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus","volume":"6","author":"Bando","year":"2016","journal-title":"J. Clin. Transl. Endocrinol."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2023.106667_bib43","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cca.2010.09.039","article-title":"HDL-C concentration is related to markers of absorption and of cholesterol synthesis: study in subjects with low vs. high HDL-C","volume":"412","author":"Nunes","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.phrs.2023.106667_bib44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ijcard.2021.01.063","article-title":"Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol","volume":"331","author":"Jojima","year":"2021","journal-title":"Int J. Cardiol."},{"key":"10.1016\/j.phrs.2023.106667_bib45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijcard.2021.02.048","article-title":"Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: any role of DPP-4 inhibitors?","volume":"330","author":"Patoulias","year":"2021","journal-title":"Int J. Cardiol."},{"issue":"10","key":"10.1016\/j.phrs.2023.106667_bib46","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.clinthera.2016.09.001","article-title":"Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes","volume":"38","author":"Heise","year":"2016","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2023.106667_bib47","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.2337\/dc21-1668","article-title":"Effect of Dapagliflozin on hematocrit in patients with type 2 diabetes at high cardiovascular risk: observations from DECLARE-TIMI 58","volume":"45","author":"Kolkailah","year":"2022","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.phrs.2023.106667_bib48","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1111\/dom.14534","article-title":"Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: a post hoc analysis of pooled data from four phase 3 randomized clinical trials","volume":"23","author":"Lund","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"21","key":"10.1016\/j.phrs.2023.106667_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11216544","article-title":"Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu","volume":"11","author":"Yaribeygi","year":"2022","journal-title":"J. Clin. Med"},{"issue":"8","key":"10.1016\/j.phrs.2023.106667_bib50","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes. Metab."},{"issue":"8","key":"10.1016\/j.phrs.2023.106667_bib51","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/dom.12481","volume":"17","author":"Nishimura","year":"2015","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2023.106667_bib52","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Invest"},{"issue":"5","key":"10.1016\/j.phrs.2023.106667_bib53","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes, Diabetes"},{"key":"10.1016\/j.phrs.2023.106667_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104215","article-title":"Cardiorenal protection of SGLT2 inhibitors-Perspectives from metabolic reprogramming","volume":"83","author":"Gao","year":"2022","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.phrs.2023.106667_bib55","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/oby.2012.59","article-title":"Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats","volume":"20","author":"Devenny","year":"2012","journal-title":"Obes. (Silver Spring)"},{"key":"10.1016\/j.phrs.2023.106667_bib56","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","article-title":"SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats","volume":"727","author":"Yokono","year":"2014","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.phrs.2023.106667_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2014.20","article-title":"Tofogliflozin, a sodium\/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models","volume":"4","author":"Suzuki","year":"2014","journal-title":"Nutr. Diabetes"},{"issue":"7","key":"10.1016\/j.phrs.2023.106667_bib58","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV Protection in the EMPA-REG OUTCOME Trial: A \"Thrifty Substrate\" Hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"issue":"20","key":"10.1016\/j.phrs.2023.106667_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012325","article-title":"Repurposing SGLT-2 inhibitors to target aging: available evidence and molecular mechanisms","volume":"23","author":"La Grotta","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2023.106667_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100176","article-title":"The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic beta-oxidation, and induces ketosis","volume":"63","author":"Wallenius","year":"2022","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.phrs.2023.106667_bib61","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ecl.2015.09.006","article-title":"Statins and diabetes","volume":"45","author":"Maki","year":"2016","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"9716","key":"10.1016\/j.phrs.2023.106667_bib62","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(10)60234-6","article-title":"Balancing the benefits of statins versus a new risk-diabetes","volume":"375","author":"Cannon","year":"2010","journal-title":"Lancet"},{"issue":"9732","key":"10.1016\/j.phrs.2023.106667_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(10)60989-0","article-title":"Statins and risk of incident diabetes","volume":"375","author":"Simpson","year":"2010","journal-title":"Lancet"},{"issue":"9716","key":"10.1016\/j.phrs.2023.106667_bib64","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"9965","key":"10.1016\/j.phrs.2023.106667_bib65","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.phrs.2023.106667_bib66","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.bbadis.2019.04.012","article-title":"Cholesterol metabolism, pancreatic beta-cell function and diabetes","volume":"1865","author":"Perego","year":"2019","journal-title":"Biochim. Et. Biophys. Acta Mol. basis Dis."},{"issue":"4","key":"10.1016\/j.phrs.2023.106667_bib67","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/eurheartj\/ehy357","article-title":"PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor","volume":"40","author":"Da Dalt","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2023.106667_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155291","article-title":"Pancreatic PCSK9 controls the organization of the beta-cell secretory pathway via LDLR-cholesterol axis","volume":"136","author":"Marku","year":"2022","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.phrs.2023.106667_bib69","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41467-020-20750-8","article-title":"An integrative multiomic network model links lipid metabolism to glucose regulation in coronary artery disease","volume":"12","author":"Cohain","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2023.106667_bib70","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/DMSO.S233538","article-title":"Extraglycemic effects of SGLT2 inhibitors: a review of the evidence","volume":"13","author":"Bonora","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.phrs.2023.106667_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/1440-1681.12963","article-title":"Exploring novel pharmacotherapeutic applications and repurposing potential of sodium glucose CoTransporter 2 inhibitors","author":"Madaan","year":"2018","journal-title":"Clin. Exp. Pharm. Physiol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823000233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823000233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:39:52Z","timestamp":1760913592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823000233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":71,"alternative-id":["S1043661823000233"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106667","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106667"}}